EUPRAXIA PHARMACEUTICALS INC
EPRX · NASDAQ
Updated at 2026-10-14 08:52:42
- Today's High
- $7.29
- Today’s Low
- $6.62
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $7.46
- Previous Close
- $7.32
- Volume
- 250.66K
- Market Cap
- $700.58M
- P/E Ratio
- --
- EPS
- $-0.94
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Biotechnology
- Sub-industry
- BIOTECHNOLOGY
- Headquarters
- 2067 CADBORO BAY ROAD, VICTORIA, BC, CANADA, V8R 5G4
- Country
- CA
- Listing Date
- 2021-03-09
- Fiscal Year End
- December
- Shares Outstanding
- 65.02M
- CIK
- 0001581178
Eupraxia Pharmaceuticals Inc. (EPRX) is a clinical-stage biotechnology company focused on advancing its proprietary drug delivery technology and the development of innovative therapies for pain and inflammatory diseases. The company's lead candidates target localized pain conditions through its Elastomeric Plasmid Delivery System, which enhances the delivery and efficacy of biologics. With a robust pipeline and a commitment to addressing significant unmet medical needs, Eupraxia aims to revolutionize the standard of care in pain management. The company is leveraging its technology platform to establish strategic partnerships and drive future growth in the dynamic biopharmaceutical landscape.
Financial Metrics
Revenue
2026-06-30
$0
2026-03-31
$0
2025-12-31
$0
2025-09-30
$0
Operating Expenses
2026-06-30
$18.1M
2026-03-31
$15.95M
2025-12-31
$16.16M
2025-09-30
$6.88M
Net Income
2026-06-30
-$14.49M
2026-03-31
-$12.65M
2025-12-31
-$16.71M
2025-09-30
-$6.36M
Net Profit Margin
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
Earnings Per Share
2026-06-30
$-0.23
2026-03-31
$-0.23
2025-12-31
$-0.37
2025-09-30
$-0.19
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
-$14.32M
2026-03-31
-$12.55M
2025-12-31
-$16.63M
2025-09-30
-$6.3M
Effective Tax Rate
2026-06-30
-0.21%
2026-03-31
-0.11%
2025-12-31
-0.06%
2025-09-30
0%
| Item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating Expenses | $18.1M | $15.95M | $16.16M | $6.88M |
| Net Income | -$14.49M | -$12.65M | -$16.71M | -$6.36M |
| Net Profit Margin | -- | -- | -- | -- |
| Earnings Per Share | $-0.23 | $-0.23 | $-0.37 | $-0.19 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | -$14.32M | -$12.55M | -$16.63M | -$6.3M |
| Effective Tax Rate | -0.21% | -0.11% | -0.06% | 0% |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.